Table 8.
Composition and assessment of the primary sequence of the multi-epitope based vaccine construct.
| Vaccines | Adjuvant used | Number of HTL | Number of CTL | Number of B cell | Length | Antigenicity | Allergenicity | Toxicity | Surface accessibility |
|---|---|---|---|---|---|---|---|---|---|
| DV-1 | BD | 6 | 5 | 5 | 352 | 0.6136 | NA | NT | Outside |
| DV-2 | RP | 5 | 4 | 2 | 336 | 0.6184 | NA | NT | Outside |
| DV-3 | HBHA | 4 | 4 | 1 | 336 | 0.6945 | NA | NT | Outside |
| DV-4 | RP | 6 | 8 | 1 | 400 | 0.6764 | NA | NT | Outside |
BD beta defensing, RP ribosomal protein, HBHA Heparin-binding hemagglutinin; NA non-allergen, NT non-toxic.